Inclusion Criteria:

          -  18 - 75 years of age with an HLA-identical sibling donor

          -  One of the following disease categories:

               -  Acute myelogenous leukemia - high risk CR1 (as evidenced by preceding MDS,
                  intermediate to high risk cytogenetics, ≥ 2 cycles to obtain CR, erythroblastic
                  or megakaryocytic leukemia; CR2+. All patients must be in CR as defined by
                  hematological recovery (ANC > 0.5x 109/L), AND <5% blasts by light microscopy
                  within the bone marrow with a cellularity of ≥15%.

               -  Acute lymphocytic leukemia - high risk CR1 [t(9;22), t (1:19), t(4;11) or other
                  MLL rearrangements] or >1cycle to obtain CR; CR2+. All patients must be in CR as
                  defined by hematological recovery (ANC > 0.5x 109/L), AND <5% blasts by light
                  microscopy within the bone marrow with a cellularity of ≥15%.

               -  Chronic myelogenous leukemia all types except blast crisis (note treated blast
                  crisis in chronic phase is eligible)

               -  Non-Hodgkin lymphoma or Hodgkin lymphoma demonstrating chemosensitive disease

               -  Myelodysplastic syndrome with severe pancytopenia, leading to either transfusion
                  dependency or increased risk for infections

          -  Performance status: Karnofsky ≥ 60%

          -  Adequate organ function within 28 days of study enrollment defined as:

               -  Liver: SGOT and SGPT < 5.0 x ULN; total bilirubin < 3 x ULN

               -  Renal: serum creatinine < 2.0 mg/dl or glomerular filtration rate (GFR) > 40
                  mL/min/1.73m2. Patients with a creatinine > 1.2 mg/dl or a history of renal
                  dysfunction must have glomerular filtration rate (GFR) > 40 mL/min/1.73m2

               -  Albumin: > 2.5 g/dL

               -  Cardiac: No decompensated CHF or uncontrolled arrhythmia; ejection fraction > 35%
                  within 6 weeks prior to study enrollment

               -  Pulmonary: No O2 requirements; DLCO > 30% predicted within 6 weeks prior to study
                  enrollment

          -  If recent mold infection (e.g. aspergillus) must have minimum of 30 days of therapy
             and responsive disease and be cleared by Infectious Disease

          -  Sexually active females of child bearing potential and males must agree to use
             effective contraception for the duration of the transplant period

          -  Voluntary written consent

        Exclusion Criteria:

          -  Pregnancy or breast feeding - women of childbearing potential must have a negative
             pregnancy test within 28 days of study enrollment.

          -  Prior myeloablative transplant within previous 3 months of study enrollment.

          -  Evidence of HIV infection or known HIV positive serology.

          -  Active serious infection.